Back Hepatitis C

Hepatitis C

New Hepatitis C Drugs Reduce Mortality Risk in First 18 Months After Treatment

For the first time, a large study has demonstrated that treatment with direct-acting antivirals (DAAs) significantly reduces mortality among people with hepatitis C virus (HCV) infection, according to a recent report in Clinical Infectious Diseases.

alt

IAS 2017: Glecaprevir/ Pibrentasvir Effective for People with HIV/HCV Coinfection

AbbVie's new 8-week pangenotypic regimen combining glecaprevir and pibrentasvir cured almost all HIV-positive people with hepatitis C coinfection in the EXPEDITION-2 study, according to a presentation at the 9th International AIDS Society Conference on HIV Science (IAS 2017) last month in Paris.

alt

San Francisco Task Force Releases First Hepatitis C Prevalence Estimates

End Hep C SF, a consortium of public health workers, medical providers, advocates, and people living with hepatitis C, has released the first-ever estimate of the number of people thought to be living with active hepatitis C virus (HCV) infection in San Francisco. 

alt

FDA Approves AbbVie's 8-Week Mavyret Combo Pill for Hepatitis C

On August 3 the U.S.Food and Drug Administration(FDA) approved AbbVie's new pangenotypic combination pill for people with hepatitis C virus (HCV) genotypes 1 through 6, to be marketed under the brand name Mavyret. Last week the European Commission gave similar approval for the European Union, where the coformulation will be sold as Maviret.

alt

HR17: Indonesian Buyers Club Helps People Obtain Generic Hepatitis C Treatment

A community-led buyers club in Indonesia has helped more than 100 people get generic direct-acting antiviral drugs to treat hepatitis C and is seeing a high cure rate, according to a presentation at the 25th Harm Reduction International Conference this month in Montreal.

alt

IAS 2017: Hepatitis C treatment is Effective and Feasible in Africa

Treatment for hepatitis C in sub-Saharan Africa can produce cure rates as high as those seen in industrialized countries, with high adherence and minimal side effects, according to a presentation this week at the 9th International AIDS Society Conference on HIV Science (IAS 2017) in Paris.

alt

FDA Approves Gilead's Vosevi Combo Pill for Hepatitis C Re-treatment

On July 18, the U.S. Food and Drug Administration(FDA) approved Gilead Sciences' Vosevi, a new once-daily combination pill containing sofosbuvir, velpatasvir, and voxilaprevir. Vosevi was approved as "salvage therapy" for people with all hepatitis C virus (HCV) genotypes who were not previously cured with prior direct-acting antiviral therapy.

alt

HR17: Hepatitis C Virus Reinfection Is Uncommon After Being Cured with DAAs

Most people on opiate substitution therapy were successfully treated for hepatitis C with an interferon-free regimen of grazoprevir/elbasvir (Zepatier), and only a small number became reinfected during 3 years of follow-up, researchers reported at the 25th Harm Reduction International Conference this week in Montreal.

alt